| Literature DB >> 24824990 |
Junkal Garmendia1, Cristina Viadas2, Laura Calatayud3, Joshua Chang Mell4, Pau Martí-Lliteras5, Begoña Euba6, Enrique Llobet5, Carmen Gil2, José Antonio Bengoechea7, Rosemary J Redfield8, Josefina Liñares3.
Abstract
Nontypable Haemophilus influenzae (NTHi) has emerged as an important opportunistic pathogen causing infection in adults suffering obstructive lung diseases. Existing evidence associates chronic infection by NTHi to the progression of the chronic respiratory disease, but specific features of NTHi associated with persistence have not been comprehensively addressed. To provide clues about adaptive strategies adopted by NTHi during persistent infection, we compared sequential persistent isolates with newly acquired isolates in sputa from six patients with chronic obstructive lung disease. Pulse field gel electrophoresis (PFGE) identified three patients with consecutive persistent strains and three with new strains. Phenotypic characterisation included infection of respiratory epithelial cells, bacterial self-aggregation, biofilm formation and resistance to antimicrobial peptides (AMP). Persistent isolates differed from new strains in showing low epithelial adhesion and inability to form biofilms when grown under continuous-flow culture conditions in microfermenters. Self-aggregation clustered the strains by patient, not by persistence. Increasing resistance to AMPs was observed for each series of persistent isolates; this was not associated with lipooligosaccharide decoration with phosphorylcholine or with lipid A acylation. Variation was further analyzed for the series of three persistent isolates recovered from patient 1. These isolates displayed comparable growth rate, natural transformation frequency and murine pulmonary infection. Genome sequencing of these three isolates revealed sequential acquisition of single-nucleotide variants in the AMP permease sapC, the heme acquisition systems hgpB, hgpC, hup and hxuC, the 3-deoxy-D-manno-octulosonic acid kinase kdkA, the long-chain fatty acid transporter ompP1, and the phosphoribosylamine glycine ligase purD. Collectively, we frame a range of pathogenic traits and a repertoire of genetic variants in the context of persistent infection by NTHi.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24824990 PMCID: PMC4019658 DOI: 10.1371/journal.pone.0097020
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinical and demographic characteristics of patients, antibiotic resistance patterns, PFGE profile and genetic features of NTHi isolates used in this study.
| Patient | Gender | Age (years) | Disease | NTHi isolate (N°) | Isolation date | Antibiotic resistance | PFGE |
|
|
|
| male | 56 | Bronchiectasis (BE) | 1a (411) | 17/2/1997 |
| A | − | 17 (off) |
| 1b (584) | 7/11/1997 | Ap, TxS | A | − | 17 (off) | ||||
| 1c (1104) | 9/11/1998 | Ap, TxS | A | − | 17 (off) | ||||
|
| male | 69 |
| 2a (628) | 15/12/1997 | Ap, TxS | B | + | 17 (off) |
| 2b (920) | 8/5/1998 | Ap, TxS | B | − | 17 (off) | ||||
|
| female | 73 | Cystic fibrosis. BE | 3a (735) | 10/2/1998 |
| C | + | 13 (on) |
| 3b (1340) | 15/6/1999 | Ap, TxS | D | + | 14 (on) | ||||
| 3c (1684) | 3/10/2000 | Ap, TxS | D | + | 14 (on) | ||||
|
| male | 64 | COPD. Emphysema | 4a (629) | 12/12/1997 | TxS | E | + | 28 (on) |
| 4b (846) | 1/4/1998 | TxS | F | + | 6 (on) | ||||
| 4c (2302) | 8/3/2002 | Susceptible | G | + | 41 (on) | ||||
| 4d (2612) | 13/1/2003 | Susceptible | H | + | 25 (on) | ||||
|
| female | 68 | COPD | 5a (322) | 12/12/1996 | TxS | I | − | 21 (on) |
| 5b (865) | 14/4/1998 | Susceptible | J | + |
| ||||
| 5c (1244) | 8/3/1999 | TxS | K | − | 36 (on) | ||||
| 5d (1715) | 16/11/2000 | Susceptible | L | − | 27 (on) | ||||
|
| male | 38 | COPD | 6a (995) | 30/6/1998 | Susceptible | M | − | 10 (on) |
| 6b (2116) | 11/12/2001 | Ap, TxS | N | − | ND |
Ap: ampicillin.
TxS: Trimethoprim-sulfomethoxazole.
COPD: Chronic Obstructive Pulmonary Disease.
Susceptible: susceptible to all antimicrobials tested.
ND: not determined.
lic2BC: the lic2BC genes encode two glycosyltransferases involved in sugar extension from HepII in the LOS molecule.
lic1A: the lic1A gene encodes a choline kinase. lic1A gene potential phase ON/OFF level of gene expression, based on the three translation initiation codons and two initiation codon-containing frames predicted for lic1A [46].
Minimal inhibitory concentrations (µg/ml) of 14 antimicrobials against 18 NTHi isolates using the microdilution method according to CLSI breakpoint criteria .
| Patient | NTHi isolate | AM | AMC | CFU | CTX | CRO | IMI | MER | TET | CHL | TxS | AZI | CIP | LEV | RIF |
|
| 1a | 2 | 4/2 | 2 | 0.25 | ≤0.12 | 0.25 | 0.5 | ≤1 | ≤1 | ≥4/76 | 0.5 | 0.03 | ≤0.5 | ≤0.25 |
| 1b | 2 | 4/2 | 2 | 0.25 | ≤0.12 | 0.25 | 0.5 | ≤1 | ≤1 | ≥4/76 | 0.5 | 0.03 | ≤0.5 | ≤0.25 | |
| 1c | 2 | 4/2 | 2 | 0.25 | ≤0.12 | 0.25 | 0.5 | ≤1 | ≤1 | ≥4/76 | 0.5 | 0.03 | ≤0.5 | ≤0.25 | |
|
| 2a | 2 | 2/1 | 1 | 0.25 | ≤0.12 | 0.25 | 0.25 | ≤1 | ≤1 | ≥4/76 | 0.25 | 0.03 | ≤0.5 | ≤0.25 |
| 2b | 2 | 2/1 | 1 | 0.25 | ≤0.12 | 0.25 | 0.25 | ≤1 | ≤1 | ≥4/76 | 0.25 | 0.03 | ≤0.5 | ≤0.25 | |
|
| 3a | 0.5 | 1/0.5 | 2 | 0.06 | ≤0.12 | 0.5 | 0.25 | ≤1 | ≤1 | 0.5/9.5 | 0.5 | 0.03 | ≤0.5 | ≤0.25 |
| 3b | ≥ 8 | 1/0.5 | 0.5 | 0.06 | ≤0.12 | 0.25 | 0.25 | ≤1 | ≤1 | ≥4/76 | 1 | 0.03 | ≤0.5 | ≤0.25 | |
| 3c | ≥ 8 | 1/0.5 | 0.5 | 0.06 | ≤0.12 | 0.25 | 0.25 | ≤1 | ≤1 | ≥4/76 | 1 | 0.03 | ≤0.5 | ≤0.25 | |
|
| 4a | 0.25 | 0.5/0.25 | 1 | 0.06 | ≤0.12 | 0.25 | 0.25 | ≤1 | ≤1 | ≥4/76 | 0.12 | 0.03 | ≤0.5 | ≤0.25 |
| 4b | 1 | 2/1 | 2 | 0.12 | ≤0.12 | 1 | 0.25 | ≤1 | ≤1 | ≥4/76 | 1 | 0.03 | ≤0.5 | ≤0.25 | |
| 4c | 0.25 | 0.5/0.25 | 1 | 0.06 | ≤0.12 | 0.12 | 0.25 | ≤1 | ≤1 | 0.5/9.5 | 0.5 | 0.03 | ≤0.5 | ≤0.25 | |
| 4d | 0.25 | 0.5/0.25 | 1 | 0.06 | ≤0.12 | 0.5 | 0.25 | ≤1 | ≤1 | 0.5/9.5 | 0.5 | 0.03 | ≤0.5 | ≤0.25 | |
|
| 5a | 0.25 | 0.5/0.25 | 1 | 0.06 | ≤0.12 | 0.25 | 0.25 | ≤1 | ≤1 | ≥4/76 | 0.12 | 0.03 | ≤0.5 | ≤0.25 |
| 5b | 1 | 1/0.5 | 2 | 0.06 | ≤0.12 | 0.5 | 0.25 | ≤1 | ≤1 | 0.5/9.5 | 0.5 | 0.03 | ≤0.5 | ≤0.25 | |
| 5c | 0.25 | 0.5/0.25 | 1 | 0.06 | ≤0.12 | 1 | 0.25 | ≤1 | ≤1 | ≥4/76 | 0.12 | 0.03 | ≤0.5 | ≤0.25 | |
| 5d | 0.5 | 1/0.5 | 2 | 0.06 | ≤0.12 | 0.12 | 0.25 | ≤1 | ≤1 | 0.5/9.5 | 2 | 0.12 | ≤0.5 | ≤0.25 | |
|
| 6a | 0.25 | 0.5/0.25 | 1 | 0.06 | ≤0.12 | 0.12 | 0.25 | ≤1 | ≤1 | ≥4/76 | 0.12 | 0.03 | ≤0.5 | ≤0.25 |
| 6b | ≥ 8 | 0.5/0.25 | 1 | 0.06 | ≤0.12 | 0.12 | 0.25 | ≤1 | ≤1 | ≥4/76 | 1 | 0.03 | ≤0.5 | ≤0.25 |
CLSI: Clinical and Laboratory Standard Institute. Breakpoint Criteria (S, susceptible; I intermediate; R, resistant): AM (Ampicillin; S≤1, I = 2, R≥4); AMC (Amoxicillin-/clavulanic acid; S≤4/2, R≥8/4); CFU (Cefuroxime; S≤4, I = 8, R≥16); CTX (Cefotaxime; S≤2); CRO (ceftriaxone; S≤2); IMI (Imipenem; S≤4); MER (Meropenem; S≤0.5); TET (Tetracycline; S≤2, I = 4, R≥8); CHL (Chloramphenicol; S≤2, I = 4, R≥8); TxS (Trimethoprim/sulfamethoxazole; S≤0.5/9.5, I = 1/19–2/38, R≥4/76); AZI (Azithromycin; S≤4); CIP (Ciprofloxacin; S≤1); LEV (Levofloxacin; S≤2); RIF (Rifampin; S≤1, I = 2, R≥4). Ref CLSI 2013.
β-lactamase producing isolate.
PCho expression by NTHi isolates.
| Patient | Isolate |
| Low reactivity (% of colonies) |
|
| NTHi1a | 71.1 | 28.9 |
| NTHi1b | 51.2 | 48.8 | |
| NTHi1c | 77.5 | 22.5 | |
|
| NTHi2a | 32.2 | 67.8 |
| NTHi2b | 5.9 | 94.1 | |
|
| NTHi3a | 93.8 | 6.2 |
| NTHi3b | 0 | 100 | |
| NTHi3c | 13.8 | 86.2 | |
|
| NTHi4a | 100 | 0 |
| NTHi4b | 10.8 | 89.2 | |
| NTHi4c | 7.3 | 92.7 | |
| NTHi4d | 47.8 | 52.2 | |
|
| NTHi5a | 100 | 0 |
| NTHi5b | 96.5 | 3.5 | |
| NTHi5c | 94.3 | 5.7 | |
| NTHi5d | 3.8 | 96.2 | |
|
| NTHi6a | 95.2 | 4.8 |
| NTHi6b | 7.2 | 92.8 |
PCho expression was detected by colony immunoblot with the anti-PCho monoclonal antibody TEPC-15. Strains were classified by colony reactivity with the TEPC-15 antibody as previously described [20]. The intensity of TEPC-15 signal rendered by each colony was determined as high or low. Percentages were calculated by assessing colony reactivity for at least 300 colonies per strain, in at least two independent experiments.
Figure 1Infection of epithelial cells by NTHi isolates recovered from chronic respiratory patients.
(A) NTHi adhesion to A549 epithelial cells. NTHi cells were incubated with A549 cells for 30 min. Bacterial adhesion was quantified by lysis, serial dilution and viable counting on sBHI-agar plates. Mean numbers for newly acquired strains (grey bar) were significantly higher (p<0.0001) than those obtained for strains recovered from patients 1, 2 and 3 (white bar). (B) Stimulation of IL-8 secretion by infection for NTHi clinical isolates. Quantification by ELISA of IL-8 secreted to the supernatant by A549 cells upon infection with NTHi1a, 1b, 1c, 2a, 2b, 3a, 3b, 3c, 5a, 5b, 5c 5d and 6a. [IL-8] was quantified at 6 (white bar) and 20 (grey bar) h post-infection.
Figure 2H. influenzae clinical isolates self-aggregation.
Tube-settling experiment of stationary phase cultures of isolates NTHi1a (open circles), NTHi1b (open squares), NTHi1c (open triangles), NTHi2a (black inverted triangle), NTHi2b (black diamond), NTHi3a (grey circle), NTHi3b (grey square), NTHi3c (grey triangle), NTHi5b (open inverted triangle) and NTHi6a (open diamond), after incubation at room temperature for 7 h. E. coli C600 (asterisk) was used as a negative control. Bacterial aggregation was quantified by measuring the decrease of absorbance at OD600nm. NTHi1a-1c self-aggregated significantly slower than NTHi2a-2b (p<0.0001 at 1 h; p<0.001 at 1.5 h). NTHi6a aggregated slower than strains from patients 1 and 2 (p<0.0001 at 1 and 1.5 h), and faster than isolates from patient 3 (p<0.0001, all time points tested).
Biofilm formation under continuous-flow conditions, in microfermenters containing glass slides where bacteria formed the biofilm.
| Patient | Isolate | OD600nm of bacterial suspension detached from glass slide |
|
| NTHi1a | 0.001 |
| NTHi1b | 0.001±0.001 | |
| NTHi1c | 0.004±0.001 | |
|
| NTHi2a | 0.0005±0.0007 |
| NTHi2b | 0.0015±0.002 | |
|
| NTHi3a | 0.0035±0.001 |
| NTHi3b | 0.012±0.016 | |
| NTHi3c | 0.154±0.21 | |
|
| NTHi5a | 1.31±0.28a |
| NTHi5b | 1.65±0.28b | |
|
| NTHi6a | 1.57±0.35a |
Data shown are means and SD of absorbance values, compared by a two tail t test. NTHi5a and NTHi6a formed a biofilm significantly higher than the non-existing ones obtained for isolates from patients 1, 2 and 3, ap<0.005. NTHi5b formed a biofilm significantly higher than the non-existing ones obtained for isolates from patients 1, 2 and 3, bp<0.0005.
NTHi strains resistance to Polymyxin B (µg/ml) mediated killing after a 60 min bacterial incubation with the AMP.
| Patient | Isolate | Polymyxin B (µg/ml) | |||||
| 1 | 0.75 | 0.5 | 0.25 | 0.125 | 0 | ||
|
| NTHi1a | 1.6±1 | 5.4±3 | 90±2.1 | 100 | 100 | 100 |
| NTHi1b | 3±1.1 | 11.1±1.3 | 86.9±4.7 | 99.6±7.4 | 95.8±3.5 | 100 | |
| NTHi1c | 3±1.7 | 8.8±0.8 | 85.8±1.7 | 95.1±9.9 | 97.2±6 | 100 | |
|
| NTHi2a | 1.4±0.9 | 6.7±2 | 86.1±10.1 | 95.6±13.5 | 100 | 100 |
| NTHi2b | 7.1±2.1 | 11.9±2.5 | 80.6±6.4 | 94.8±1.2 | 99±8 | 100 | |
|
| NTHi3a | 4±3 | 8.1±1.9 | 90.2±0,9 | 100 | 100 | 100 |
| NTHi3b | 12±4.5 | 19.2±10.5 | 78.7±7.9 | 98.4±4.8 | 100 | 100 | |
| NTHi3c | 9±1.1 | 19.5±4.6 | 98.3±9.2 | 98.9±6.6 | 100 | 100 | |
|
| NTHi4a | 3.9±0.9 | 10.7±2.8 | 83.2±3.2 | 100 | 98.8±2.5 | 100 |
|
| NTHi5a | 4.6±1.2 | 7±2.8 | 86.8±6.2 | 100 | 100 | 100 |
| NTHi5b | 3.8±2.2 | 8.7±3.4 | 83.5±11.8 | 100 | 100 | 100 | |
|
| NTHi6a | 8.8±3.7 | 16±5.9 | 86.8±2.1 | 100 | 100 | 100 |
p<0.05 vs. first strain with identical PFGE profile isolated from each patient.
NTHi strains resistance to Polymyxin B and to human β-defensin 1 mediated killing after a 30 min bacterial incubation with the AMP.
| AMP | Patient | Isolate | [AMP] (µg/ml) | |||
| 1 | 0.75 | 0.5 | 0 | |||
|
|
| NTHi1a | 11.8±0.9 | 30.9±1.7 | 96±12.7 | 100 |
| NTHi1b | 35.5±9.6 | 69.3±9.4 | 100 | 100 | ||
| NTHi1c | 36.7±8 | 78.1±9.2 | 100 | 100 | ||
|
| NTHi2a | 12.9±1.5 | 54.6±11.1 | 96.7±5.1 | 100 | |
| NTHi2b | 37.2±6.3 | 74.3±2 | 99.8±9.9 | 100 | ||
|
| NTHi3a | 26.5±7.3 | 49±2.2 | 98.8±7.4 | 100 | |
| NTHi3b | 34.4±3.4 | 55.4±11.5 | 100 | 100 | ||
| NTHi3c | 51.7±6.1 | 75.1±4 | 100 | 100 | ||
|
|
| NTHi1a | 57.3±3.8 | 88.8±7.7 | ND | 100 |
| NTHi1b | 84.5±3.7 | 100±5 | ND | 100 | ||
| NTHi1c | 91.2±4 | 100 | ND | 100 | ||
|
| NTHi2a | 60.7±7.5 | 91.7±3.7 | ND | 100 | |
| NTHi2b | 87.5±3.5 | 100 | ND | 100 | ||
|
| NTHi3a | 68.3±9.6 | 90.6±3.7 | ND | 100 | |
| NTHi3b | 87.1±0.6 | 100 | ND | 100 | ||
| NTHi3c | 94.8±2.8 | 100 | ND | 100 | ||
*ND = not determined.
p<0.05 vs. first strain with identical PFGE profile isolated from each patient.
List of open reading frames (ORFs) with single nucleotide variants (SNVs) among isolates NTHi1a, 1b and 1c.
| ORF | Alt | NTHi1a | NTHi1b | NTHi1c | aaref | aaalt | aapos | Proteinlength | Genename | HiRdKW20(%aa id) | 86-028NP(%aa id) | Function |
| 64 | A | 0 | 0 | 1 | E | K | 269 | 297 |
| HI0072 (99) | NTHI0084 (99) | Inorganic polyphosphate/ATP-NAD kinase |
| 140 | G | 0 | 0 | 1 | T | A | 162 | 705 |
| HI1741 (99) | NTHI2052 (99) | Guanosine-3′,5′-bis(di-P) 3′-pyrophosphohydrolase |
| 156 | G | 0 | 0 | 1 | D | G | 398 | 996 |
| Hi0712 (86) | NTHI0840,out of frame | Haemoglobin-haptoglobin binding protein |
| A | 0 | 1 | 1 | E | K | 433 | ||||||
| T | 0 | 1 | 1 | T | I | 895 | ||||||
| 345 | T | 0 | 1 | 1 | G | V | 96 | 455 |
| Hi0401 (90) | NTHI0522 (88) | Long-chain fatty acid ABC transporter |
| 423 | A | 0 | 0 | 1 | G | D | 400 | 401 | Hi0477 (99) | NTHI0607 (99) | Tyrosine-specific transport protein 1 | |
| 583 | T | 0 | 0 | 1 | A | S | 139 | 658 |
| Hi0583 (98) | NTHI0741 (98) | 2′,3′-cyclic nucleotide 2′-phosphodiesterase/3′-nucleotidase |
| 587 | A | 0 | 0 | 1 | T | K | 525 | 756 |
| Hi0661 (81) | NTHI0782 (86) | Hemoglobin-haptoglobin binding protein B |
| 1001 | G | 0 | 1 | 1 | T | A | 79 | 296 |
| Hi1640 (99) | NTHI1399 (99) | ABC transporter permease |
| 1009 | A | 0 | 1 | 1 | P | T | 280 | 910 |
| Hi1217 (92) | NTHI1390 (90) | Heme utilization protein |
| T | 0 | 0 | 1 | D | Y | 291 | ||||||
| G | 0 | 0 | 1 | T | A | 555 | ||||||
| 1057 | A | 0 | 0 | 1 | A | D | 255 | 385 |
| Hi1172 (98) | NTHI1340 (99) | S-adenosylmethionine synthetase |
| 1127 | A | 0 | 0 | 1 | R | S | 85 | 196 |
| Hi0901 (96) | NTHI1068 (99) | Dinucleoside polyphosphate hydrolase |
| 1140 | A | 0 | 1 | 1 | P | T | 278 | 430 |
| Hi0888 (98) | NTHI1052 (98) | Phosphoribosylamine-glycine ligase |
| 1146 | G | 0 | 0 | 1 | T | A | 2 | 457 | Hi0883 (99) | NTHI1046 (99) | Na+/alanine symporter | |
| 1153 | A | 0 | 0 | 1 | E | K | 395 | 404 |
| HI0877 (95) | NTHI1040 (96) | GTPase |
| 1155 | G | 0 | 1 | 1 | G | G | 223 | 435 |
| NTHI1038 (98) | Aminopeptidase | |
| 1301 | G | 0 | 1 | 1 | P | P | 34 | 516 |
| Hi0661 (85) | NTHI0782 (82) | Hemoglobin-haptoglobin binding protein B |
| C | 0 | 1 | 1 | S | L | 40 | ||||||
| T | 0 | 1 | 1 | S | L | 40 | ||||||
| A | 0 | 1 | 1 | S | L | 40 | ||||||
| C | 0 | 1 | 1 | R | R | 44 | ||||||
| C | 0 | 1 | 1 | Y | H | 116 | ||||||
| A | 0 | 1 | 1 | D | N | 320 | ||||||
| 1389 | T | 0 | 1 | 1 | G | G | 164 | 449 |
| Hi0972 (99) | NTHI1145 (99) | Acetyl-CoA carboxylase biotin carboxylase subunit |
| 1448 | G | 0 | 0 | 1 | G | G | 54 | 615 | Hi1051 (99) | NTHI1212 (99) | Multidrug ABC transporter | |
| 1499 | T | 0 | 0 | 1 | A | V | 346 | 408 | Hi1104 (99) | Transporter protein | ||
| 1594 | C | 0 | 1 | 1 | Q | H | 226 | 242 |
| Hi0260.1 (97) | NTHI0369 (88) | 3-deoxy-D-manno-octulosonic-acid kinase |
| 1596 | A | 0 | 1 | 1 | W | * | 133 | 734 |
| Hi0262 (94) | NTHI0369 (88) | heme-hemopexin utilization protein C |
| 1638 | G | 0 | 1 | 1 | R | R | 234 | 489 |
| Hi0221 (99) | NTHI0324 (99) | Inosine 5′-monophosphate dehydrogenase |
| 1641 | G | 0 | 0 | 1 | V | G | 23 | 376 |
| Hi0139 (78) | NTHI0225 (79) | Outer membrane protein |
| C | 0 | 1 | 0 | I | T | 91 | ||||||
| C | 0 | 1 | 1 | I | P | 91 | ||||||
| G | 0 | 1 | 1 | E | G | 181 | ||||||
| T | 0 | 0 | 1 | R | I | 225 | ||||||
| A | 0 | 1 | 1 | V | I | 228 | ||||||
| A | 0 | 1 | 0 | S | * | 229 | ||||||
| T | 0 | 0 | 1 | A | S | 230 | ||||||
| T | 0 | 0 | 1 | A | S | 233 | ||||||
| C | 0 | 1 | 1 | T | P | 271 | ||||||
| G | 0 | 1 | 1 | Y | D | 273 | ||||||
| C | 0 | 1 | 0 | T | P | 275 | ||||||
| G | 0 | 1 | 1 | I | R | 277 |
ORF: open reading frame number in NTHi1a annotation.
Alt: nucleotide showing a SNP.
0: nucleotide identical to the one in strain NTHi1a; 1: SNV, compared to NTHi1a.
aa ref: amino acid in NTHi1a; aa alt: amino acid replacement due to SNV: aa position: replacement location.
ORFs in grey follow the pattern 0-1-1, i.e. ORFs with SNVs in NTHi1b and 1c, when compared to NTHi1a.